Bibliography
- JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, THUN MJ: Cancer statistics, 2007. CA. Cancer J. Clin. (2007) 57(1):43-66.
- GILBOA E: The makings of a tumor rejection antigen. Immunity (1999) 11(3):263-270.
- NOSSAL GJ: Host immunobiology and vaccine development. Lancet (1997) 350(9087):1316-1319.
- SATO E, OLSON SH, AHN J et al.: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA (2005) 102(51):18538-18543.
- CURIEL TJ, COUKOS G, ZOU L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. (2004) 10(9):942-949.
- BURNET M: Cancer; a biological approach. I. The processes of control. Br. Med. J. (1957) 1(5022):779-786.
- BURNET FM: Immunological surveillance in neoplasia. Transplant. Rev. (1971) 7:3-25.
- BURNET FM: The concept of immunological surveillance. Prog. Exp. Tumor Res. (1970) 13:1-27.
- BURNET M: Immunological factors in the process of carcinogenesis. Br. Med. Bull. (1964) 20:154-158.
- DUNN GP, OLD LJ, SCHREIBER RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 21(2):137-148.
- MARINCOLA FM, JAFFEE EM, HICKLIN DJ, FERRONE S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. (2000) 74:181-273.
- GIRARDI M, GLUSAC E, FILLER RB et al.: The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J. Exp. Med. (2003) 198(5):747-755.
- GERMAIN RN, MARGULIES DH: The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. (1993) 11:403-450.
- SCHWARTZ RH: Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell (1992) 71(7):1065-1068.
- CHEN C, NABAVI N: In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity (1994) 1(2):147-154.
- CLEMENTE CG, MIHM MC Jr, BUFALINO R, ZURRIDA S, COLLINI P, CASCINELLI N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 77(7):1303-1310.
- HARTVEIT F: Breast cancer: poor short-term prognosis in cases with moderate lymphocyte infiltration at the tumour edge: a preliminary report. Oncol. Rep. (1998) 5(2):423-426.
- SCHUMACHER K, HAENSCH W, ROEFZAAD C, SCHLAG PM: Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. (2001) 61(10):3932-3936.
- FUNADA Y, NOGUCHI T, KIKUCHI R, TAKENO S, UCHIDA Y, GABBERT HE: Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol. Rep. (2003) 10(2):309-313.
- GUIDOBONI M, GAFA R, VIEL A et al.: Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am. J. Pathol. (2001) 159(1):297-304.
- NAITO Y, SAITO K, SHIIBA K et al.: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. (1998) 58(16):3491-3494.
- ZHANG L, CONEJO-GARCIA JR, KATSAROS D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. (2003) 348(3):203-213.
- HURWITZ AA, YU TF, LEACH DR, ALLISON JP: CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA (1998) 95(17):10067-10071.
- TALMADGE JE: Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. (2007) 13(18):5243-5248.
- UYTTENHOVE C, PILOTTE L, THEATE I et al.: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. (2003) 9(10):1269-1274.
- SEDLMAYR P, BLASCHITZ A, WINTERSTEIGER R et al.: Localization of indoleamine 2,3-dioxygenase in human female reproductive organs and the placenta. Mol. Hum. Reprod. (2002) 8(4):385-391.
- SCHROECKSNADEL K, WINKLER C, FUITH LC, FUCHS D: Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett. (2005) 223(2):323-329.
- ISHIO T, GOTO S, TAHARA K, TONE S, KAWANO K, KITANO S: Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. (2004) 19(3):319-326.
- MELLOR AL, MUNN DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. (2004) 4(10):762-774.
- OKAMOTO A, NIKAIDO T, OCHIAI K et al.: Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. (2005) 11(16):6030-6039.
- SHIMIZU J, YAMAZAKI S, SAKAGUCHI S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. (1999) 163(10):5211-5218.
- TERABE M, MATSUI S, NOBEN-TRAUTH N et al.: NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. (2000) 1(6):515-520.
- WOO EY, CHU CS, GOLETZ TJ et al.: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. (2001) 61(12):4766-4772.
- ODUNSI K, JUNGBLUTH AA, STOCKERT E et al.: NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. (2003) 63(18):6076-6083.
- BRICHARD V, VAN PEL A, WOLFEL T et al.: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. (1993) 178(2):489-495.
- GOODELL V, SALAZAR LG, URBAN N et al.: Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J. Clin. Oncol. (2006) 24(5):762-768.
- BERCHUCK A, KOHLER MF, MARKS JR, WISEMAN R, BOYD J, BAST RC Jr: The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol. (1994) 170(1 Part 1):246-252.
- BERNS EM, KLIJN JG, VAN PUTTEN WL et al.: p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J. Clin. Oncol. (1998) 16(1):121-127.
- BRAITHWAITE AW, STURZBECHER HW, ADDISON C, PALMER C, RUDGE K, JENKINS JR: Mouse p53 inhibits SV40 origin-dependent DNA replication. Nature (1987) 329(6138):458-460.
- BROWN R, CLUGSTON C, BURNS P et al.: Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer (1993) 55(4):678-684.
- ELLEDGE RM, ALLRED DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res. Treat. (1994) 32(1):39-47.
- ELTABBAKH GH, BELINSON JL, KENNEDY AW et al.: p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer (1997) 80(5):892-898.
- HARTMANN LC, PODRATZ KC, KEENEY GL et al.: Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J. Clin. Oncol. (1994) 12(1):64-69.
- HAINAUT P, HERNANDEZ T, ROBINSON A et al.: IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. (1998) 26(1):205-213.
- LAMB P, CRAWFORD L: Characterization of the human p53 gene. Mol. Cell. Biol. (1986) 6(5):1379-1385.
- MARKS JR, DAVIDOFF AM, KERNS BJ et al.: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. (1991) 51(11):2979-2984.
- RELES A, WEN WH, SCHMIDER A et al.: Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. (2001) 7(10):2984-2997.
- RIGHETTI SC, DELLA TORRE G, PILOTTI S et al.: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. (1996) 56(4):689-693.
- ROTTER V, ABUTBUL H, BEN-ZE'EV A: P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts. EMBO J. (1983) 2(7):1041-1047.
- HUANG HJ, NEVEN P, DRIJKONINGEN M et al.: Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J. Clin. Pathol. (2005) 58(6):611-616.
- AFIFY AM, WERNESS BA, MARK HF: HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Exp. Mol. Pathol. (1999) 66(2):163-169.
- BERCHUCK A, KAMEL A, WHITAKER R et al.: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. (1990) 50(13):4087-4091.
- LOHRISCH C, PICCART M: An overview of HER2. Semin. Oncol. (2001) 28(6 Suppl. 18):3-11.
- MEDEN H, KUHN W: Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur. J. Obstet. Gynecol. Reprod. Biol. (1997) 71(2):173-179.
- LASSUS H, LEMINEN A, VAYRYNEN A et al.: ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol. Oncol. (2004) 92(1):31-39.
- RUBIN SC, FINSTAD CL, WONG GY, ALMADRONES L, PLANTE M, LLOYD KO: Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am. J. Obstet. Gynecol. (1993) 168(1 Part 1):162-169.
- SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244(4905):707-712.
- SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
- SCANLAN MJ, CHEN YT, WILLIAMSON B et al.: Characterization of human colon cancer antigens recognized by autologous antibodies. Int. J. Cancer (1998) 76(5):652-658.
- ODUNSI K, TERRY G, HO L, BELL J, CUZICK J, GANESAN TS: Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int. J. Cancer (1996) 67(5):595-602.
- TINDLE RW: Human papillomavirus vaccines for cervical cancer. Curr. Opin. Immunol. (1996) 8(5):643-650.
- GURE AO, CHUA R, WILLIAMSON B et al.: Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin. Cancer Res. (2005) 11(22):8055-8062.
- SIMPSON AJ, CABALLERO OL, JUNGBLUTH A, CHEN YT, OLD LJ: Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer (2005) 5(8):615-625.
- KNUTSON KL, ALMAND B, DANG Y, DISIS ML: Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. (2004) 64(3):1146-1151.
- MANJILI MH, ARNOUK H, KNUTSON KL et al.: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce “danger signals”. Breast Cancer Res. Treat. (2006) 96(3):233-241.
- KMIECIAK M, KNUTSON KL, DUMUR CI, MANJILI MH: HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur. J. Immunol. (2007) 37(3):675-685.
- CASEY G, LOPEZ ME, RAMOS JC et al.: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene (1996) 13(9):1971-1981.
- KOHLER MF, KERNS BJ, HUMPHREY PA, MARKS JR, BAST RC Jr, BERCHUCK A: Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet. Gynecol. (1993) 81(5 Part 1):643-650.
- HENRIKSEN R, STRANG P, BACKSTROM T, WILANDER E, TRIBUKAIT B, OBERG K: Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. Anticancer Res. (1994) 14(2B):603-608.
- VAN DER ZEE AG, HOLLEMA H, SUURMEIJER AJ et al.: Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol. (1995) 13(1):70-78.
- ELIOPOULOS AG, KERR DJ, HEROD J et al.: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene (1995) 11(7):1217-1228.
- PEREGO P, GIAROLA M, RIGHETTI SC et al.: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. (1996) 56(3):556-562.
- HAVRILESKY LJ, ELBENDARY A, HURTEAU JA, WHITAKER RS, RODRIGUEZ GC, BERCHUCK A: Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet. Gynecol. (1995) 85(6):1007-1010.
- CHEN YT, SCANLAN MJ, SAHIN U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA (1997) 94(5):1914-1918.
- FACOETTI A, NANO R, ZELINI P et al.: Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin. Cancer Res. (2005) 11(23):8304-8311.
- ATKINS D, FERRONE S, SCHMAHL GE, STORKEL S, SELIGER B: Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J. Urol. (2004) 171(2 Part 1):885-889.
- AARNOUDSE CA, VAN DEN DOEL PB, HEEMSKERK B, SCHRIER PI: Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int. J. Cancer (1999) 82(3):442-448.
- YANG T, LAPINSKI PE, ZHAO H et al.: A rare transporter associated with antigen processing polymorphism overpresented in HLAlow colon cancer reveals the functional significance of the signature domain in antigen processing. Clin. Cancer Res. (2005) 11(10):3614-3623.
- MONOS DS, PAPPAS J, MAGIRA EE et al.: Identification of HLA-DQalpha and -DRbeta residues associated with susceptibility and protection to epithelial ovarian cancer. Hum. Immunol. (2005) 66(5):554-562.
- KUSS I, SAITO T, JOHNSON JT, WHITESIDE TL: Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin. Cancer Res. (1999) 5(2):329-334.
- COCA S, PEREZ-PIQUERAS J, MARTINEZ D et al.: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer (1997) 79(12):2320-2328.
- DOLCETTI R, VIEL A, DOGLIONI C et al.: High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am. J. Pathol. (1999) 154(6):1805-1813.
- KOCH M, BECKHOVE P, OP DEN WINKEL J et al.: Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann. Surg. (2006) 244(6):986-992; discussion 983-992.
- OUDEJANS JJ, HARIJADI H, KUMMER JA et al.: High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. J. Pathol. (2002) 198(4):468-475.
- DE VRIES IJ, BERNSEN MR, VAN GELOOF WL et al.: In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Cancer Immunol. Immunother. (2007) 56(10):1667-1676.
- HAANEN JB, BAARS A, GOMEZ R et al.: Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. (2006) 55(4):451-458.
- KNUTSON KL, CURIEL TJ, SALAZAR L, DISIS ML: Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematol. Oncol. Clin. North Am. (2003) 17(4):1051-1073.
- SHEVACH EM: CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. (2002) 2(6):389-400.
- ZIEGLER SF: FOXP3: not just for regulatory T cells anymore. Eur. J. Immunol. (2007) 37(1):21-23.
- GAO Q, QIU SJ, FAN J et al.: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. (2007) 25(18):2586-2593.
- TEMPFER C, HEFLER L, HAEUSLER G et al.: Serum M3/M21 in ovarian cancer patients. Br. J. Cancer (1997) 76(10):1387-1389.
- LEONG SP, PENG M, ZHOU YM, VAQUERANO JE, CHANG JW: Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann. Surg. Oncol. (2002) 9(1):82-87.
- PIER GB, LYCZAK JB, WETZLER LM: Immunology, Infection and Immunity. ASM press (2004).
- JANEWAY CA: Immunobiology, 5th Edition, Garland Publishing (2001).
- STROM: Prognostic Implications of Defining Natural Killer Cell Function and T-Cell Sub-Sets in Patients with Squamous Cell Carcinoma. Marcel Dekker (1990):89-93.
- MUKHOPADHYAYA R, RAO RS, FAKIH AR, GANGAL SG: Detection of circulating immune complexes in patients with squamous cell carcinoma of the oral cavity. J. Clin. Lab. Immunol. (1986) 21(4):189-193.
- BOOKMAN MA, DARCY KM, CLARKE-PEARSON D, BOOTHBY RA, HOROWITZ IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the gynecologic oncology group. J. Clin. Oncol. (2003) 21(2):283-290.